This work was supported by the German Research foundation (WE 3548/4-1) and Roland-Ernst-Stiftung f&#252;r Gesundheitswesen (1/14).

The animal experiments presented here were independently reviewed and permitted by an institutional and a governmental Animal Care and Use Committee and were conducted according to Federation of Laboratory Animal Science Associations (FELASA) guidelines. All possible measures were taken to minimize suffering including anesthesia and analgesia or, if necessary, premature euthanasia.
1. Preparation of Cells and Organoids
NOTE: Use a volume of 20 &#181;L with 100,000 cells for each injection. Use basement membrane matrix (BMM) in order to prevent leakage and ensure standardized injection. In order to ensure reproducible results, conduct cell line authentication assays (e.g., via STR profiling) at regular intervals.
<ol>
	<li>Preparation of primary cell suspensions from fresh tissue 
	NOTE: Always work under sterile conditions. Immediate transfer of the freshly resected tissue from the operating room to the laboratory on ice is required to ensure high viability of the cells. 
	The patient&#39;s well-being and optimal treatment must always be the first priority. Therefore, tissue samples for research must be obtained in a manner that does not interfere with the subsequent pathological work-up and staging of the resected tumor. In most cases, it is therefore reasonable to have the samples for research obtained by a trained pathologist in order to ensure non-interference with the pathological diagnosis.
	<ol>
		<li>Immediately after sterile removal from the resected specimen (ideally ~1 cm3), place the tissue sample in a 50 mL tube pre-filled with 20-30 mL of phosphate-buffered saline (PBS). Store the tube on ice and transfer to the laboratory immediately.</li>
		<li>Put the tissue in a Petri dish and wash it twice with plenty of PBS to remove the remaining blood.</li>
		<li>Cut the tissue into small pieces (~ 2-4 mm) with a scalpel (e.g., with a #20 or #36 blade).</li>
		<li>Use the dissociator according to the manufacturer&#39;s instructions in order to further dissociate the tumor tissue to a single-cell suspension. Alternatively, use other protocols of enzymatic tumor digestion.</li>
		<li>Count the cells of the resulting single-cell suspension (e.g., in a coulter counter or a hemocytometer).</li>
		<li>Centrifuge (5 min at 1,500 x g) and wash the cell suspension twice with PBS.</li>
		<li>Resuspend the cells in BMM at a concentration of 5 x 106 cells/mL and keep them on ice.</li>
	</ol>
	</li>
	<li>Preparation of cell lines for injection
	<ol>
		<li>Grow all colorectal cancer cell lines under standard culturing conditions (37 &#176;C, 5% CO2) and prepare them at the day of surgery.</li>
		<li>Harvest the cells according to standard cell culture protocols, count the cells (e.g., in a coulter counter or a hemocytometer) and calculate the required amount for all injections depending on the numbers of animals to be injected.</li>
		<li>Prepare 3-5x of the actually needed volume to account for pipetting losses and the dead volume of the injection syringe.</li>
		<li>Centrifuge (5 min at 1,500 g) and wash the cell suspension twice with PBS.</li>
		<li>Resuspend the cells in BMM at a concentration of 5 x 106 cells/mL and keep them on ice.</li>
	</ol>
	</li>
	<li>Organoid preparation 
	NOTE: All 3D organoid cultures are grown under standard culturing conditions (37 &#176;C, 5% CO2). Detailed protocols for organoid culture have been published before.18,19,20 Similar to conventional cell lines, we recommend a volume of 20 &#181;L BMM with 100,000 cells per injection. The organoids are prepared at the day of surgery as follows:
	<ol>
		<li>Prepare the following medium (in the following referred to as DMEM/F12+++): Advanced Dulbecco&#39;s Modified Eagle&#39;s Medium (DMEM)/F12 + 1% HEPES (1M) + 1% Glutamine (200 mM) + 1% Penicillin/Streptomycin.</li>
		<li>Pre-fill 15 mL tubes with 1 mL DMEM/F12+++.</li>
		<li>Carefully aspirate the organoids from the surface of the culture plate and transfer the contents of 3 to 5 wells into one 15 mL tube.</li>
		<li>Carefully break the organoids up into smaller pieces by pipetting them up and down with an extended glass pipette.</li>
		<li>Add 5 mL DMEM/F12+++ to the tube, followed by centrifugation at 1,000 x g for 5 min.</li>
		<li>After centrifugation, remove the supernatant, resuspend the pellet in 600 &#181;L enzymatic dissociation buffer and transfer the suspension to one well of a 6-well plate.</li>
		<li>Incubate at 37 &#176;C for 1-5 min and then carefully pipet the suspension up and down in order to dissolve the organoids. 
		NOTE: Verify the digestion via microscope; it is complete when all cell clusters have been dissociated to single cells.</li>
		<li>Upon successful digestion, add 1.4 mL of DMEM/F12+++ to stop the digestion. Then transfer all wells of digested organoids to a 50 mL tube.</li>
		<li>Count the cells and calculate the required amount for all injections.</li>
		<li>Prepare 3 - 5x of the actually needed volume to account for pipetting losses and the dead volume of the injection syringe</li>
		<li>Centrifuge (5 min at 1,500 x g) and wash the cell suspension twice with PBS.</li>
		<li>Resuspended the cells in BMM to a concentration of 5 x 106 cells/mL and keep them on ice.</li>
	</ol>
	</li>
</ol>
2. Orthotopic Mouse Model
<ol>
	<li>Preparation of recipient animals for surgery 
	NOTE: Use 6-8 week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice as recipients.21 NSG are among the most immunocompromised mice, lacking mature B, T and NK cells along with multiple other immune defects.21 They reliably grow tumors even if low cell numbers are injected and are highly prone to distant metastases. NSG mice are excellent breeders and can be kept in conventional specific pathogen free (SPF) units.
	<ol>
		<li>Prior to the first incision, inject 0.05 mg/kg of buprenorphine subcutaneously.</li>
		<li>Use sevoflurane at 3-3.5 vol% for general anesthesia. A loss of the toe pinch reflex indicates sufficient anesthesia.</li>
		<li>Cover the eyes of the anesthetized mice with ophthalmic ointment to avoid desiccation of the cornea.</li>
		<li>Restrain the mice in a supine position on a small table.</li>
		<li>Shave the abdomen with an electric shaver (depilatory cream can be used alternatively) and disinfect with at least 3 times clorhexidine/iodine and 70% alcohol alternatively.</li>
		<li>Cover the surgical field with sterile drapes. 
		NOTE: The use of perioperative antibiotics is optional and subject to institutional guidelines.</li>
	</ol>
	</li>
	<li>Midline laparotomy and exposure of the cecum
	<ol>
		<li>Use scissors (scalpels can be used alternatively) to make a small midline incision (3 - 5 mm) of the skin on the lower abdomen. Pick up the abdominal wall musculature with forceps and carefully incise it with scissors, thus opening the abdominal cavity.</li>
		<li>Identify and carefully exteriorize the cecum with atraumatic forceps. Position the blind ending pouch of the cecum on the abdomen pointing cranially.</li>
		<li>Once exteriorized, keep the cecum moist using warm saline swabs at all times.</li>
	</ol>
	</li>
	<li>Orthotopic injection, closure of the abdomen and postoperative recovery
	<ol>
		<li>For intracecal injection, use a standard 1 mL syringe with a 30 G cannula. Mount this syringe on a microinjection pump, which is in turn mounted on a micromanipulator.</li>
		<li>Carefully grasp the tip of the cecum with atraumatic forceps and gently smoothen it by stroking it downward with a second set of forceps moistened with warm saline.</li>
		<li>Position the cannula directly above the cecum.</li>
		<li>Perform the following steps under visual control with a binocular surgical microscope.</li>
		<li>Carefully grasp the cecum with two atraumatic forceps at both ends of the exteriorized part of the cecum, slightly stretch it and then slowly pull it over the cannula which is positioned parallel and directly above. It is crucial not to perforate the entire bowel wall (thus injecting the cells into the lumen) as well as not to perforate the serosa beyond the initial point of penetration, as this would lead to leakage and peritoneal dissemination.
		<ol>
			<li>Move the bowel towards the cannula, not the cannula towards the bowel. Hold and stretch the bowel between two forceps. The surgeon&#39;s hands must be resting on a surface in order to reduce tremor.</li>
		</ol>
		</li>
		<li>Inject the cells between the serosa (seen as very thin, translucent lining above the intramural blood vessels) and the muscularis. The cannula must therefore be visually placed above the blood vessels and underneath the thin translucent membrane.</li>
		<li>Use a foot switch to start the injection in order to reduce tremor while the cannula is inside the bowel wall.</li>
		<li>Once the cannula is in position, start the injection. Use a duration of 20 s, resulting in 1 &#181;L/s setting on the control unit of the pump. 
		NOTE: The injection into or near a damaged blood vessel leads to direct intravascular dissemination and distant metastasis and should therefore be avoided.</li>
		<li>After completion of the injection, carefully remove the cannula by pulling it backward.</li>
		<li>Place a dry swab under the cecum, and then thoroughly rinse the cecum with distilled water in order to lyse leaked cells and thus prevent artificial peritoneal dissemination.</li>
	</ol>
	</li>
	<li>Closure of the abdomen and postoperative recovery
	<ol>
		<li>After rinsing, gently return the cecum to the abdominal cavity.</li>
		<li>Close the abdominal wall with 6-0 rapidly absorbable running sutures.</li>
		<li>Close the skin with surgical wound clips.</li>
		<li>Place the mouse on a heating map set to 38 &#176;C until it has fully recovered from the anesthesia.</li>
		<li>Closely observe the postoperative condition of the mice for the following 48 h. In case of distress, treat with 0.05 mg/kg buprenorphine every 12 h.</li>
		<li>Monitor the mice at least once daily for signs of distress due to tumor growth.</li>
	</ol>
	</li>
</ol>
3. Isolation of Circulating Tumor Cells from Whole Blood Samples
NOTE: Obtain blood by transcutaneous cardiac puncture on anesthetized mice, followed by euthanasia. Ideally, 1,000 &#181;L of blood are drawn into a syringe prefilled with 100 &#181;L of an anticoagulant (Ethylenediaminetetraacetic acid (EDTA) or heparin). Use an anti-human-EpCAM (epithelial cell adhesion molecule) antibody to identify the CTCs. This works very well if human epithelial cell lines are used in the mouse model. For other appliances, different antibodies may be required.
<ol>
	<li>CTC enrichment:
	<ol>
		<li>Pre-fill 15 mL tubes with 5 mL density gradient medium and carefully transfer the blood into the 15 mL tube.</li>
		<li>Centrifuge (30 min at 300 x g without brake) and carefully remove the upper supernatant.</li>
		<li>Pour the rest into a new 15 mL tube and centrifuge (15 min, 300 x g with brake).</li>
		<li>Recover the interphase containing the mononuclear cells (discard the rest) and wash the cells twice with PBS.</li>
		<li>Resuspend the pellet in 200 &#181;L PBS/1% EDTA and add 4 &#181;L of EpCAM antibody. Incubate 20 min on ice in the dark.</li>
	</ol>
	</li>
	<li>Screening and picking
	<ol>
		<li>Prepare the following buffer (in the following referred to as picking buffer): PBS + 10% fetal calf serum (FCS) + 1% Penicillin/Streptomycin (1%) + 0.8% EDTA.</li>
		<li>Use a PAP pen to draw a ~1 cm circle in a 6 cm sterile Petri dish (prevents the fluid from dispersing in the dish), and pipet 700 &#181;L of picking buffer into this circle.</li>
		<li>Add 50 &#181;L of cell suspension to the 700 &#181;L picking buffer within the circle. Check the density of cells with the microscope. Split the sample into different dishes if it is too dense.</li>
		<li>Wait for the cells to settle down (~5 min).</li>
		<li>Screen the drop of cell suspension for stained (= EpCAM-positive) cells.</li>
		<li>Once a cell is found, pick the cell with the micromanipulator and put it in 50 &#181;L buffer depending on the intended downstream analysis (e.g., RNA extraction buffer or culturing medium).</li>
		<li>Depending on the intended downstream analyses, isolate EpCAM-negative cells and/or medium as negative controls.</li>
		<li>Proceed with downstream analyses (e.g., cell culture, PCR).</li>
	</ol>
	</li>
</ol>

<ol>
	<li>Siegel, R. L., Miller, K. D., Jemal, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer+statistics,+2016.">Cancer statistics, 2016.</a> CA Cancer J Clin. 66 (1), 7-30 (2016).</li><li>Weitz, J., Koch, M., Debus, J., H&#246;hler, T., Galle, P. R., B&#252;chler, M. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Colorectal+cancer.">Colorectal cancer.</a> Lancet. 365 (9454), 153-165 (2005).</li><li>Sch&#246;lch, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Circulating+tumor+cells+of+colorectal+cancer.">Circulating tumor cells of colorectal cancer.</a> Cancer Cell Microenviron. 1 (5), (2014).</li><li>Steinert, G., Sch&#246;lch, S., Koch, M., Weitz, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Biology+and+significance+of+circulating+and+disseminated+tumour+cells+in+colorectal+cancer.">Biology and significance of circulating and disseminated tumour cells in colorectal cancer.</a> Langenbecks Arch Surg. 397 (4), 535-542 (2012).</li><li>Bork, U., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prognostic+relevance+of+minimal+residual+disease+in+colorectal+cancer.">Prognostic relevance of minimal residual disease in colorectal cancer.</a> World J Gastroenterol. 20 (30), 10296-10304 (2014).</li><li>Bork, U., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Circulating+tumour+cells+and+outcome+in+non-metastatic+colorectal+cancer:+a+prospective+study.">Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.</a> Br J Cancer. 112 (8), 1306-1313 (2015).</li><li>Rahbari, N. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Compartmental+differences+of+circulating+tumor+cells+in+colorectal+cancer.">Compartmental differences of circulating tumor cells in colorectal cancer.</a> Ann Surg Oncol. 19 (7), 2195-2202 (2012).</li><li>Rahbari, N. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Metastatic+Spread+Emerging+From+Liver+Metastases+of+Colorectal+Cancer:+Does+the+Seed+Leave+the+Soil+Again?.">Metastatic Spread Emerging From Liver Metastases of Colorectal Cancer: Does the Seed Leave the Soil Again?.</a> Ann Surg. 263 (2), 345-352 (2016).</li><li>Rahbari, N. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Meta-analysis+shows+that+detection+of+circulating+tumor+cells+indicates+poor+prognosis+in+patients+with+colorectal+cancer.">Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer.</a> Gastroenterology. 138 (5), 1714-1726 (2010).</li><li>Steinert, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immune+Escape+and+Survival+Mechanisms+in+Circulating+Tumor+Cells+of+Colorectal+Cancer.">Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer.</a> Cancer Res. 74 (6), 1694-1704 (2014).</li><li>Sharpless, N. E., Depinho, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+mighty+mouse:+genetically+engineered+mouse+models+in+cancer+drug+development.">The mighty mouse: genetically engineered mouse models in cancer drug development.</a> Nat Rev Drug Discov. 5 (9), 741-754 (2006).</li><li>Roper, J., Hung, K. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Priceless+GEMMs:+genetically+engineered+mouse+models+for+colorectal+cancer+drug+development.">Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.</a> Trends Pharmacol Sci. 33 (8), 449-455 (2012).</li><li>Sch&#246;lch, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Radiotherapy+combined+with+TLR7/8+activation+induces+strong+immune+responses+against+gastrointestinal+tumors.">Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.</a> Oncotarget. 6 (7), 4663-4676 (2015).</li><li>Sch&#246;lch, S., Rauber, C., Weitz, J., Koch, M., Huber, P. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TLR+activation+and+ionizing+radiation+induce+strong+immune+responses+against+multiple+tumor+entities.">TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities.</a> Oncoimmunology. 4 (11), e1042201 (2015).</li><li>Sch&#246;lch, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Circulating+tumor+cells+exhibit+stem+cell+characteristics+in+an+orthotopic+mouse+model+of+colorectal+cancer.">Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.</a> Oncotarget. 7 (19), 27232-27242 (2016).</li><li>Nanduri, L. K., Garc&#237;a, S., Weitz, J., Sch&#246;lch, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mouse+Models+of+Colorectal+Cancer-Derived+Circulating+Tumor+Cells.">Mouse Models of Colorectal Cancer-Derived Circulating Tumor Cells.</a> Med Chem (Los Angeles). 6 (7), 497-499 (2016).</li><li>van Noort, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Novel+Drug+Candidates+for+the+Treatment+of+Metastatic+Colorectal+Cancer+through+Global+Inverse+Gene-Expression+Profiling.">Novel Drug Candidates for the Treatment of Metastatic Colorectal Cancer through Global Inverse Gene-Expression Profiling.</a> Cancer Res. 74 (20), 5690-5699 (2014).</li><li>Sato, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Long-term+expansion+of+epithelial+organoids+from+human+colon,+adenoma,+adenocarcinoma,+and+Barrett's+epithelium.">Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.</a> Gastroenterology. 141 (5), 1762-1772 (2011).</li><li>Boj, S. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Organoid+models+of+human+and+mouse+ductal+pancreatic+cancer.">Organoid models of human and mouse ductal pancreatic cancer.</a> Cell. 160 (1-2), 324-338 (2015).</li><li>Gao, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Organoid+cultures+derived+from+patients+with+advanced+prostate+cancer.">Organoid cultures derived from patients with advanced prostate cancer.</a> Cell. 159 (1), 176-187 (2014).</li><li>Ito, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=NOD/SCID/gamma(c)(null)+mouse:+an+excellent+recipient+mouse+model+for+engraftment+of+human+cells.">NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.</a> Blood. 100 (9), 3175-3182 (2002).</li><li>Simon, M. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+comparative+phenotypic+and+genomic+analysis+of+C57BL/6J+and+C57BL/6N+mouse+strains.">A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains.</a> Genome Biol. 14 (7), R82 (2013).</li><li>Kalish, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=C57BL/6N+Mice+Are+More+Resistant+to+Ehrlich+Ascites+Tumors+Than+C57BL/6J+Mice:+The+Role+of+Macrophage+Nitric+Oxide.">C57BL/6N Mice Are More Resistant to Ehrlich Ascites Tumors Than C57BL/6J Mice: The Role of Macrophage Nitric Oxide.</a> Med Sci Monit Basic Res. 21, 235-240 (2015).</li><li>Tseng, W., Leong, X., Engleman, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Orthotopic+mouse+model+of+colorectal+cancer.">Orthotopic mouse model of colorectal cancer.</a> J Vis Exp. (10), e484 (2007).</li><li>Roper, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Combination+PI3K/MEK+inhibition+promotes+tumor+apoptosis+and+regression+in+PIK3CA+wild-type,+KRAS+mutant+colorectal+cancer.">Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.</a> Cancer Lett. 347 (2), 204-211 (2014).</li><li>Coffee, E. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Concomitant+BRAF+and+PI3K/mTOR+blockade+is+required+for+effective+treatment+of+BRAF(V600E)+colorectal+cancer.">Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.</a> Clin Cancer Res. 19 (10), 2688-2698 (2013).</li><li>Belmont, P. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Resistance+to+dual+blockade+of+the+kinases+PI3K+and+mTOR+in+KRAS-mutant+colorectal+cancer+models+results+in+combined+sensitivity+to+inhibition+of+the+receptor+tyrosine+kinase+EGFR.">Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.</a> Sci Signal. 7 (351), ra107 (2014).</li><li>Hung, K. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+a+mouse+model+for+sporadic+and+metastatic+colon+tumors+and+its+use+in+assessing+drug+treatment.">Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.</a> Proc Natl Acad Sci USA. 107 (4), 1565-1570 (2010).</li><li>Wang, F., Johnson, R. L., Snyder, P. W., DeSmet, M. L., Fleet, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+Inducible,+Large-Intestine-Specific+Transgenic+Mouse+Model+for+Colitis+and+Colitis-Induced+Colon+Cancer+Research.">An Inducible, Large-Intestine-Specific Transgenic Mouse Model for Colitis and Colitis-Induced Colon Cancer Research.</a> Dig Dis Sci. 61 (4), 1069-1079 (2016).</li><li>Xue, Y., Johnson, R., Desmet, M., Snyder, P. W., Fleet, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+a+transgenic+mouse+for+colorectal+cancer+research+with+intestinal+cre+expression+limited+to+the+large+intestine.">Generation of a transgenic mouse for colorectal cancer research with intestinal cre expression limited to the large intestine.</a> Mol Cancer Res. 8 (8), 1095-1104 (2010).</li><li>Tetteh, P. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+an+inducible+colon-specific+Cre+enzyme+mouse+line+for+colon+cancer+research.">Generation of an inducible colon-specific Cre enzyme mouse line for colon cancer research.</a> Proc Natl Acad Sci USA. 113 (42), 11859-11864 (2016).</li></ol>

The authors have nothing to disclose.

Despite their preclinically proven activity in subcutaneous mouse models, the great majority of novel compounds fail in clinical trials and never reach the clinic.11 This obvious insufficiency of subcutaneous mouse models to accurately simulate the biology and growth patterns of tumors has led to the development of orthotopic mouse models based on the injection of tumor cells directly into the original organ.
Orthotopic mouse models are able to simulate the biology and ...

Colorectal cancer (CRC) is one of the most common causes of cancer death in western countries.1 While the primary tumor can often be resected, the occurrence of distant metastases dramatically worsens the prognosis and often leads to death.2,3 The biological correlate of metastasis is circulating tumor cells (CTCs), which detach from the tumor, survive in circulation, attach to the epithelium in the target organ, invade the organ and ultimately outgrow to new lesions.4 Although CTCs are known to be of prognostic relevance,5,6,7,8,9 their biology is only partly understood as a result of their extreme rarity in CRC.10
Mouse models are a powerful tool to study various aspects of cancer biology. Classical, subcutaneous tumor models are produced by subcutaneous injection of tumor cells into recipient mice, which can be either immunocompetent (if syngeneic murine tumor cells are used) or immunodeficient. Subcutaneous tumor models are inexpensive and produce data fast; their end-point tumor growth can be easily and non-invasively measured. However, 88% of new compounds that have demonstrated antitumor activity in such models fail in clinical trials.11 This is in part due to interspecies differences between humans and mice; however, a large part of this failure is due to the low predictive value of subcutaneous mouse models.
Orthotopic mouse models, in which the tumor cells are injected into the organ of origin and thus grow in their original microenvironment, are therefore increasingly used in cancer research.11,12,13,14 Orthotopic models do not only simulate local tumor growth conditions; as a result of the anatomically correct site of tumor growth, orthotopic mouse models also allow realistic simulation of metastasis and are therefore used to study CTC biology8,15,16 or their response to different treatments in CRC.13,17
A major disadvantage of orthotopic mouse models is their technical complexity. Depending on the organ in which the cells are to be injected, the learning curve until the experimenter is able to induce reproducible tumors is rather long. This especially applies to colorectal cancer models, as the tumor cells need to be injected into the bowel wall, which often results in perforation, tumor cell leakage or endoluminal tumor cell loss. This article is intended to describe the method of cell preparation from primary tissue samples, 2D cell lines and 3D organoid culture and their injection into the cecum of mice. The technique described here leads to highly uniform tumors and, depending on the tumor biology of the cell line used for injection, reproducible formation of distant metastases and CTCs in the recipient mice.15

<table><tbody><tr><td>&lt;strong&gt;Cell culture Media and Components&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Advanced DMEM F12</td><td>Invitrogen</td><td>12634010</td><td>DMEM/ F12 +++ medium</td></tr><tr><td>HEPES (1 M)</td><td>Life Technologies GmbH</td><td>15630056</td><td>DMEM/ F12 +++ medium</td></tr><tr><td>Glutamax-I Supplement (200 mM)</td><td>Life Technologies GmbH</td><td>35050038</td><td>DMEM/ F12 +++ medium</td></tr><tr><td>Penicillin/Streptomycin (PenStrep)</td><td>Life Technologies GmbH</td><td>15140122</td><td>DMEM/ F12 +++ medium</td></tr><tr><td>DMEM</td><td>Life Technologies GmbH</td><td>61965026</td><td>basic medium of 2D cell lines (DMEM/10% FCS)</td></tr><tr><td>Fetal Calf Serum (FCS)</td><td>BIOCHROM AG</td><td>S 0115</td><td>basic medium of 2D cell lines (DMEM/10% FCS)</td></tr><tr><td>TrypLE Express enzymatic dissociation buffer</td><td>Life Technologies GmbH</td><td>12604021</td><td></td></tr><tr><td>Matrigel basement membrane matrix (BMM, phenol red free)</td><td>CORNING B.V. Life Sciences</td><td>356231</td><td></td></tr><tr><td>Dulbecco&#039;s Phosphate Buffered Saline</td><td>Life Technologies GmbH</td><td>14190169</td><td></td></tr><tr><td>Trypsin-EDTA (0.25%, Phenol-Red)</td><td>Life Technologies GmbH</td><td>25200072</td><td></td></tr><tr><td>6-/48-well plates with lid</td><td>CORNING</td><td>3516/3548</td><td></td></tr><tr><td>cell culture flask 75 cm&amp;sup2;, 250 mL</td><td>VWR International GmbH</td><td>734-2066</td><td></td></tr><tr><td>cell culture flask 150 cm&amp;sup2;, 600 mL</td><td>Corning B.V. Life Sciences</td><td>355001</td><td></td></tr><tr><td>Eppendorf tubes 1,5 mL / 2 mL</td><td>Sarstedt AG &amp;amp; Co.</td><td>72.706.400/ 72.695.400</td><td></td></tr><tr><td>15 mL, 50 mL centrifuge tubes</td><td>Greiner-Bio-One GmbH</td><td>188271/227270</td><td></td></tr><tr><td>TC10 Counting Slides (for TC20 Counting Machine)</td><td>Bio-Rad Laboratories GmbH</td><td>1450016</td><td></td></tr><tr><td>Pasteur pipettes (glass, 150 mm)</td><td>Fisher Scientific GmbH</td><td>11546963/ FB50251</td><td>thinly pulled by using a bunsen burner</td></tr><tr><td>gentleMACS Dissociator</td><td>Miltenyi Biotec</td><td>130-093-235</td><td>for primary tumor tissue preparation</td></tr><tr><td>MACSmix Tube Rotator</td><td>Miltenyi Biotec</td><td>130-090-753</td><td>for primary tumor tissue preparation</td></tr><tr><td>gentleMACS C Tubes</td><td>Miltenyi Biotec</td><td>130-093-237</td><td>for primary tumor tissue preparation</td></tr><tr><td>Human Tumor Dissociation Kit</td><td>Miltenyi Biotec</td><td>130-095-929</td><td>for primary tumor tissue preparation</td></tr><tr><td>Falcon 70 &amp;micro;m Cell Strainer</td><td>Corning B.V. Life Sciences</td><td>352350</td><td>for primary tumor tissue preparation</td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company&lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;Surgical Equipment&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Sevoflurane</td><td>AbbVie Germany GmbH &amp;amp; Co. KG</td><td>-</td><td></td></tr><tr><td>Medical oxygen</td><td>Air Liquide Medical GmbH</td><td>-</td><td></td></tr><tr><td>Buprenorphine</td><td>Temgesic</td><td>-</td><td></td></tr><tr><td>Bepanthen - opthalmic ointment</td><td>Bayer Vital GmbH</td><td>10047757</td><td></td></tr><tr><td>Normal saline 0.9% (E154)</td><td>Serumwerk Bernburg AG</td><td>10013</td><td></td></tr><tr><td>Aqua ad injectabilia</td><td>Braun</td><td>235144</td><td></td></tr><tr><td>1 mL Syringe (without dead volume) - Injekt-F SOLO</td><td>Braun/neoLab</td><td>194291661</td><td></td></tr><tr><td>30G injection needle</td><td>BECTON DICKINSON</td><td>304000</td><td></td></tr><tr><td>cellulose swabs</td><td>Lohmann &amp;amp; Rauscher Deutschland</td><td>13356</td><td></td></tr><tr><td>Micro-Adson Forceps</td><td>FST - Fine Science Tools</td><td>11018-12</td><td></td></tr><tr><td>Iris Scissor - ToughCut</td><td>FST - Fine Science Tools</td><td>14058-11</td><td></td></tr><tr><td>Olsen-Hegar Needle Holder</td><td>FST - Fine Science Tools</td><td>12002-12</td><td></td></tr><tr><td>AutoClip Kit</td><td>FST - Fine Science Tools</td><td>12020-00</td><td></td></tr><tr><td>PDS Z1012H 6/0 C1 (surgical suture)</td><td>Johnson &amp;amp; Johnson Medical GmbH</td><td>Z1012H</td><td></td></tr><tr><td>Table Top Research Anesthesia Machine w/O2 Flush and a Sevoflurane Vaporizer</td><td>Parkland Scientific</td><td>V3000PS/PK</td><td></td></tr><tr><td>UltraMicro Pump with Micro4 Controller</td><td>World Precision Instruments</td><td>UMP3-4</td><td>equipment for highly controlled orthotopic injection</td></tr><tr><td>Footswitch for SYS-Micro4 Controller</td><td>World Precision Instruments</td><td>15867</td><td>equipment for highly controlled orthotopic injection</td></tr><tr><td>Three-axis Manual Micromanipulator</td><td>World Precision Instruments</td><td>M325</td><td>equipment for highly controlled orthotopic injection</td></tr><tr><td>Magnetic Stand for Micromanipulator</td><td>World Precision Instruments</td><td>M10</td><td>equipment for highly controlled orthotopic injection</td></tr><tr><td>Steel Base Plate for M10 Magnetic Stand</td><td>World Precision Instruments</td><td>5479</td><td>equipment for highly controlled orthotopic injection</td></tr><tr><td>Hot Plate 062</td><td>Labotect</td><td>13854</td><td></td></tr><tr><td>Isis - Hair shaver</td><td>AESCULAP - Braun</td><td>-</td><td></td></tr><tr><td>Binocular Surgical Microscope</td><td>Parkland Scientific</td><td>VS-2Z</td><td></td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company&lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;CTC isolation&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>EDTA</td><td>Roth</td><td>8040.1</td><td></td></tr><tr><td>Density gradient medium &amp;ndash; Ficoll</td><td>StemCell - Lymphoprep</td><td>7801</td><td></td></tr><tr><td>Alexa Fluor 488 anti-human CD326 (EpCAM) Antibody clone 9C4</td><td>BioLegend</td><td>324210</td><td></td></tr><tr><td>Alexa Fluor 488 anti-mouse CD326 (EpCAM) Antibody clone G8.8</td><td>BioLegend</td><td>118210</td><td></td></tr><tr><td>Petri Dish, &amp;oslash; 60 x 15 mm, 21 cm&amp;sup2;, Vent</td><td>Greiner bio-one</td><td>628102</td><td></td></tr><tr><td>Fluorescence Cell Culture Microscope</td><td>Leica</td><td></td><td></td></tr><tr><td>Transferman 4r Micromanipulator</td><td>Eppendorf</td><td></td><td></td></tr><tr><td>CellTram Air</td><td>Eppendorf</td><td></td><td>aspiration pump connected to the micromanipulator</td></tr><tr><td>Dmz Universal Microelectrode Puller</td><td>Dagan Corporation</td><td></td><td>required for the manufacturing of micro capillaries for single cell aspiration</td></tr><tr><td>Prism Glass Capillaries</td><td>Dagan Corporation</td><td></td><td></td></tr><tr><td>PAP pen</td><td>Abcam</td><td>ab2601</td><td></td></tr><tr><td>Dulbecco&#039;s Phosphate Buffered Saline</td><td>Life Technologies GmbH</td><td>14190169</td><td>picking buffer</td></tr><tr><td>Fetal Calf Serum (FCS)</td><td>BIOCHROM AG</td><td>S 0115</td><td>picking buffer</td></tr><tr><td>Penicillin/Streptomycin (PenStrep)</td><td>Life Technologies GmbH</td><td>15140122</td><td>picking buffer</td></tr><tr><td>EDTA</td><td>Roth</td><td>8040.1</td><td>picking buffer</td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company&lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;Immunohistochemistry&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Purified anti-human CD326 (EpCAM) antibody clone 9C4</td><td>BioLegend</td><td>324201</td><td>EpCAM immunohistochemistry (cf, fig 2C)</td></tr><tr><td>HRP rabbit anti-mouse IgG</td><td>Abcam</td><td>ab97046</td><td>EpCAM immunohistochemistry (cf, fig 2C)</td></tr></tbody></table>

isolation of circulating tumor cells in an orthotopic mouse model of colorectal cancer

Despite the advantages of easy applicability and cost-effectiveness, subcutaneous mouse models have severe limitations and do not accurately simulate tumor biology and tumor cell dissemination. Orthotopic mouse models have been introduced to overcome these limitations; however, such models are technically demanding, especially in hollow organs such as the large bowel. In order to produce uniform tumors which reliably grow and metastasize, standardized techniques of tumor cell preparation and injection are critical. 
We have developed an orthotopic mouse model of colorectal cancer (CRC) which develops highly uniform tumors and can be used for tumor biology studies as well as therapeutic trials. Tumor cells from either primary tumors, 2-dimensional (2D) cell lines or 3-dimensional (3D) organoids are injected into the cecum and, depending on the metastatic potential of the injected tumor cells, form highly metastatic tumors. In addition, CTCs can be found regularly. We here describe the technique of tumor cell preparation from both 2D cell lines and 3D organoids as well as primary tumor tissue, the surgical and injection techniques as well as the isolation of CTCs from the tumor-bearing mice, and present tips for troubleshooting.

The successful and reproducible generation of colorectal tumors in this model critically depends on accurate injection of the cells without spillage or leakage. If this is achieved, this model is extremely reliable and very rarely results in artificial peritoneal dissemination. The growth kinetics of the tumors as well as their dissemination patterns depend on the biology of the used organoids and cells.15 While HCT116 cells reliably metastasize to the liver in thi...

Watch this Scientific Journal Video about Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer at JoVE.com

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

We describe the establishment of orthotopic colorectal tumors via injection of tumor cells or organoids into the cecum of mice and the subsequent isolation of circulating tumor cells (CTCs) from this model.

Despite the advantages of easy applicability and cost-effectiveness, subcutaneous mouse models have severe limitations and do not accurately simulate ...

isolation-circulating-tumor-cells-an-orthotopic-mouse-model

Universidad San Sebastian

Research

JoVE Journal

Cancer Research

9.9K Views.  Technische Universität Dresden. We describe the establishment of orthotopic colorectal tumors via injection of tumor cells or organoids into the cecum of mice and the subsequent isolation of circulating tumor cells (CTCs) from this model. 

Video: Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Metastasis is the major cause of cancer death. The role of circulating tumor cells (CTCs) in promoting cancer metastasis, in which lung colonization by CTCs critically contributes to early lung metastatic processes, has been vigorously investigated. As such, animal models are the only approach that captures the full systemic process of metastasis. Given that problems occur in previous experimental designs for examining the contributions of CTCs to blood vessel extravasation, we established an in vivo lung colonization assay in which a long-term-fluorescence cell-tracer, carboxyfluorescein succinimidyl ester (CFSE), was used to label suspended tumor cells and lung perfusion was performed to clear non-specifically trapped CTCs prior to lung removal, confocal imaging, and quantification. Polymeric fibronectin (polyFN) assembled on CTC surfaces has been found to mediate lung colonization in the final establishment of metastatic tumor tissues. Here, to specifically test the requirement of polyFN assembly on CTCs for lung colonization and extravasation, we performed short term lung colonization assays in which suspended Lewis lung carcinoma cells (LLCs) stably expressing FN-shRNA (shFN) or scramble-shRNA (shScr) and pre-labeled with 20 &#956;M of CFSE were intravenously inoculated into C57BL/6 mice. We successfully demonstrated that the abilities of shFN LLC cells to colonize the mouse lungs were significantly diminished in comparison to shScr LLC cells. Therefore, this short-term methodology may be widely applied to specifically demonstrate the ability of CTCs within the circulation to colonize the lungs.

An animal model is needed to decipher the role of circulating tumor cells (CTCs) in promoting lung colonization during cancer metastasis. Here, we established and successfully performed an in vivo assay to specifically test the requirement of polymeric fibronectin (polyFN) assembly on CTCs for lung colonization.

Metastasis is the major cause of cancer death. The role of circulating tumor cells (CTCs) in promoting cancer metastasis, in which lung colonization by ...

Orthotopic Mouse Model of Colorectal Cancer

The traditional subcutaneous tumor model is less than ideal for studying colorectal cancer. Orthotopic mouse models of colorectal cancer, which feature cancer cells growing in their natural location, replicate human disease with high fidelity. Two techniques can be used to establish this model. Both techniques are similar and require mouse anesthesia and laparotomy for exposure of the cecum. One technique involves injection of a colorectal cancer cell suspension into the cecal wall. Cancer cells are first grown in culture, harvested when subconfluent and prepared as a single cell suspension. A small volume of cells is injected slowly to avoid leakage. The other technique involves transplantation of a piece of subcutaneous tumor onto the cecum. A mouse with a previously established subcutaneous colorectal tumor is euthanized and the tumor is removed using sterile technique. The tumor piece is divided into small pieces for transplantation to another mouse. Prior to transplantation, the cecal wall is lightly damaged to facilitate tumor cell infiltration. The time to developing primary tumors and liver metastases will vary depending on the technique, cell line, and mouse species used. This orthotopic mouse model is useful for studying the natural progression of colorectal cancer and testing new therapeutic agents against colorectal cancer.

Two techniques can be used to establish this model: injection of a cancer cell suspension into the cecal wall or transplantation of a piece of subcutaneous tumor onto the cecum. This model is useful for studying the natural progression of colorectal cancer and testing new therapeutic agents against colorectal cancer.

The traditional subcutaneous tumor model is less than ideal for studying colorectal cancer. Orthotopic mouse models of colorectal cancer, which feature ...

Biology

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Metastasis is a leading cause of cancer death. Despite improvements in treatment strategies, metastatic cancer has a poor prognosis. We thus face an urgent need to understand the mechanisms behind metastasis development, and thus to propose efficient treatments for advanced cancer. Metastatic cancers are hard to treat, as biopsies are invasive and inaccessible. Recently, there has been considerable interest in liquid biopsies including both cell-free circulating deoxyribonucleic acid (DNA) and circulating tumor cells from peripheral blood and we have established several circulating tumor cell lines from metastatic colorectal cancer patients to participate in their characterization. Indeed, to functionally characterize these rare and poorly described cells, the crucial step is to expand them. Once established, circulating tumor cell (CTC) lines can then be cultured in suspension or adherent conditions. At the molecular level, CTC lines can be further used to assess the expression of specific markers of interest (such as differentiation, epithelial or cancer stem cells) by immunofluorescence or cytometry analysis. In addition, CTC lines can be used to assess drug sensitivity to gold-standard chemotherapies as well as to targeted therapies. The ability of CTC lines to initiate tumors can also be tested by subcutaneous injection of CTCs in immunodeficient mice.
Finally, it is possible to test the role of specific genes of interest that might be involved in cancer dissemination by editing CTC genes, by short hairpin ribonucleic acid (shRNA) or Crispr/Cas9. Modified CTCs can thus be injected into immunodeficient mouse spleens, to experimentally mimic part of the metastatic development process in vivo.
In conclusion, CTC lines are a precious tool for future research and for personalized medicine, where they will allow prediction of treatment efficiency using the very cells that are originally responsible for metastasis.

Culturing CTCs allows a deeper functional characterization of cancer, through assaying specific marker expression, and assessing drug resistance and the ability to colonize the liver among other possibilities. Overall, CTC culture could be a promising clinical tool for personalized medicine to improve patient outcome.

Metastasis is a leading cause of cancer death. Despite improvements in treatment strategies, metastatic cancer has a poor prognosis. We thus face an ...

An Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis

Ovarian cancer is characterized by early, diffuse metastasis with 70% of women having metastatic disease at the time of diagnosis. While elegant transgenic mouse models of ovarian cancer exist, these mice are expensive and take a long time to develop tumors. Intraperitoneal injection xenograft models lack human stroma and do not accurately model ovarian cancer metastasis. Even patient derived xenografts (PDX) do not fully recapitulate the human stromal microenvironment as serial PDX passages demonstrate significant loss of human stroma. The ability to easily model human ovarian cancer within a physiologically relevant stromal microenvironment is an unmet need. Here, the protocol presents an orthotopic ovarian cancer mouse model using human ovarian cancer cells combined with patient-derived carcinoma-associated mesenchymal stem cells (CA-MSCs). CA-MSCs are stromal progenitor cells, which drive the formation of the stromal microenvironment and support ovarian cancer growth and metastasis. This model develops early and diffuses metastasis mimicking clinical presentation. In this model, luciferase expressing ovarian cancer cells are mixed in a 1:1 ratio with CA-MSCs and injected into the ovarian bursa of NSG mice. Tumor growth and metastasis are followed serially over time using bioluminescence imaging. The resulting tumors grow aggressively and form abdominal metastases by 14 days post injection. Mice experienced significant decreases in body weight as a marker of systemic illness and increased disease burden. By day 30 post injection, mice met endpoint criteria of &gt;10% body weight loss and necropsy confirmed intra-abdominal metastasis in 100% of mice and 60%-80% lung and parenchymal liver metastasis. Collectively, orthotopic engraftment of ovarian cancer cells and stroma cells generates tumors that closely mimic the early and diffuse metastatic behavior of human ovarian cancer. Furthermore, this model provides a tool to study the role of ovarian cancer cell: stroma cell interactions in metastatic progression.

Orthotopic engraftment of ovarian cancer cells mixed with human stromal cells provides a mouse model that exhibits rapid, diffuse metastatic behavior that is characteristic of human ovarian cancer. This model also allows for the study of tumor cell and stromal cell interactions, as well as their role in tumor progression and metastasis.

Ovarian cancer is characterized by early, diffuse metastasis with 70% of women having metastatic disease at the time of diagnosis. While elegant ...

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Hepatic metastasis of colorectal cancer (CRC) is a leading cause of cancer-related death. Cancer-associated fibroblasts (CAFs), a major component of the tumor microenvironment, play a crucial role in metastatic CRC progression and predict poor patient prognosis. However, there is a lack of satisfactory mouse models to study the crosstalk between metastatic cancer cells and CAFs. Here, we present a method to investigate how liver metastasis progression is regulated by the metastatic niche and possibly could be restrained by stroma-directed therapy. Portal vein injection of CRC organoids generated a desmoplastic reaction, which faithfully recapitulated the fibroblast-rich histology of human CRC liver metastases. This model was tissue-specific with a higher tumor burden in the liver when compared to an intra-splenic injection model, simplifying mouse survival analyses. By injecting luciferase-expressing tumor organoids, tumor growth kinetics could be monitored by in vivo imaging. Moreover, this preclinical model provides a useful platform to assess the efficacy of therapeutics targeting the tumor mesenchyme. We describe methods to examine whether adeno-associated virus-mediated delivery of a tumor-inhibiting stromal gene to hepatocytes could remodel the tumor microenvironment and improve mouse survival. This approach enables the development and assessment of novel therapeutic strategies to inhibit hepatic metastasis of CRC.

Portal vein injection of colorectal cancer (CRC) organoids generates stroma-rich liver metastasis. This mouse model of CRC hepatic metastasis represents a useful tool to study tumor-stroma interactions and develop novel stroma-directed therapeutics such as adeno-associated virus-mediated gene therapies.

Hepatic metastasis of colorectal cancer (CRC) is a leading cause of cancer-related death. Cancer-associated fibroblasts (CAFs), a major component of the ...

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Over the last decade, more sophisticated preclinical colorectal cancer (CRC) models have been established using patient-derived cancer cells and 3D tumoroids. Since patient derived tumor organoids can retain the characteristics of the original tumor, these reliable preclinical models enable cancer drug screening and the study of drug resistance mechanisms. However, CRC related death in patients is mostly associated with the presence of metastatic disease. It is therefore essential to evaluate the efficacy of anti-cancer therapies in relevant in vivo models that truly recapitulate the key molecular features of human cancer metastasis. We have established an orthotopic model based on the injection of CRC patient-derived cancer cells directly into the cecum wall of mice. These tumor cells develop primary tumors in the cecum that metastasize to the liver and lungs, which is frequently observed in patients with advanced CRC. This CRC mouse model can be used to evaluate drug responses monitored by microcomputed tomography (&#181;CT), a clinically relevant small-scale imaging method that can easily identify primary tumors or metastases in patients. Here, we describe the surgical procedure and the required methodology to implant patient-derived cancer cells in the cecum wall of immunodeficient mice.

This protocol describes the orthotopic implantation of patient-derived cancer cells in the cecum wall of immunodeficient mice. The model recapitulates advanced colorectal cancer metastatic disease and allows for the evaluation of new therapeutic drugs in a clinically relevant scenario of lung and liver metastases.

Over the last decade, more sophisticated preclinical colorectal cancer (CRC) models have been established using patient-derived cancer cells and 3D ...

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Cancer metastasis is the foremost cause of cancer-associated deaths. Recent studies have shown that circulating tumor cells (CTCs) are important in cancer metastasis. Indeed, the number of CTCs correlates with tumor size. Here, a detailed description is provided of a methodology for isolation and propagation of CTCs from a syngeneic mouse model of hepatocellular carcinoma (HCC) which allows for downstream analysis of potentially important molecular mechanisms of solid organ tumor metastasis. This method is efficient and reproducible. It is a non-invasive technique and, therefore, has potential to replace the invasive biopsy of tissues from humans which may be associated with complications. Therefore, the method discussed here allows for the isolation and propagation of CTCs from whole blood samples such that they can be examined and characterized. This has potential for future adaptation for clinical applications such as diagnosis, and personalized targeted therapy.

Circulating tumor cells (CTCs) have been shown to play an important role in tumor metastasis. Here, a method for the isolation and propagation of CTCs from the whole blood of a syngeneic mouse tumor model of hepatocellular carcinoma (HCC) metastasis is described.

Cancer metastasis is the foremost cause of cancer-associated deaths. Recent studies have shown that circulating tumor cells (CTCs) are important in cancer ...

Medicine

Intracecal Tumor Cell Injection: A Technique to Deliver Cancer Cells for Establishing Orthotopic Colorectal Cancer Mouse Model

Source: Kochall, S., et al. <a href="https://www-jove-com.bdigitaluss.remotexs.co/v/55357"> Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer </a> J. Vis. Exp. (2017)
The video describes the technique for intracecal injection of cancerous cells to develop an orthotopic mouse model with highly uniform tumors. Therefore, the orthotopic mouse model allows realistic simulation of metastasis, providing a valuable tool to study the phenotype changes during tumor growth and dissemination.

Source: Kochall, S., et al.  Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer  J. Vis. Exp. (2017)
The video ...

JoVE Encyclopedia of Experiments

Colorectal Cancer

Animal model studies

Establishing Experimental Metastases Mouse Model: Implanting GFP Expressing CRC Organoid Cells in PDX Model to Detect Micrometastases

Source: Okazawa, Y. et al.&#160; <a href="https://www-jove-com.bdigitaluss.remotexs.co/v/57374"> High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor.</a> J. Vis. Exp. (2018).
This video describes the protocol for generating metastases by the PDX derived CRC organoids labeled with GFP lentivirus into the spleen of an immunodeficient mouse. Cancer micrometastases colonizing other organs can be detected using a fluorescence microscope to assess the GFP expression.

Source: Okazawa, Y. et al.&#160;  High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a ...

Spontaneous Metastasis Mouse Models: A Platform to Study the Metastatic Potential of Orthotopically Injected Colorectal Cancer Cells

Source: Okazawa, Y., et al. <a href="https://www-jove-com.bdigitaluss.remotexs.co/v/57374"> High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor.</a>&#160;J. Vis. Exp.&#160;(2018).
This video describes the protocol to establish a spontaneous metastasis mouse model of colorectal cancer patient-derived xenografts or PDXs. These xenograft models partially mimic the features of human carcinomas and understand the critical aspects of human malignancies, including invasion and metastasis.&#160;